Articles tagged with Drug Discovery
A team of researchers from Michigan and Connecticut has received an award for their work on a new antibiotic, linezolid. The drug is the first of its kind to be approved in 35 years and shows promise in treating serious Gram-positive infections that are resistant to conventional antibiotics.
Rensselaer researchers develop a new biocatalysis lab-on-a-slide technique to screen for NADPH oxidase inhibitors, potentially leading to effective therapies for cardiovascular disease. The method allows for faster and more cost-effective discovery of new drugs.
Roth's discovery led to the development of Lipitor, which has logged more than 36-million patient years of experience and involved over 400 clinical trials. His innovative approach to statin structure resulted in a simpler molecule with equal efficacy.
Researchers at the University of Illinois Chicago have successfully synthesized amphidinolide T1, a highly potent compound with potential as an antitumor agent. The breakthrough, achieved through retrosynthetic analysis and sophisticated technologies, could lead to more effective cancer treatments.
A new compound has been discovered that can inhibit the formation of biofilms in bacteria, which are often lethal to patients with compromised immune systems. The compound works by disrupting quorum sensing, a process that allows bacterial cells to communicate and mount an effective attack.
Researchers have found a novel group of bacteria in tropical ocean sediments that produce molecules with potential in treating infectious diseases and cancer. The discovery has opened up a new source for drug discovery, with thousands of strains available.
Researchers found that Nocaine is a weak reinforcer, providing some of cocaine's effects but at a lower level. This makes it less likely to be abused and have abuse-related toxicity.
The world's first cloned double 'knockout' pigs represent a major boost to xenotransplantation research, offering hope for resolving the organ shortage. Researchers predict human clinical trials for pig islet transplantation in patients with diabetes and kidney transplants could be imminent.
Two new drugs, Dapivirine and R165335, have shown great promise in Phase I and II clinical trials against drug-resistant HIV strains. These compounds are derived from the dianilinopyrimidine family and have been tested as a viable candidate for treating AIDS in developing countries.
A study by Georgetown University researchers found that initially recommended drug dosages are often too high, which can lead to unnecessary overdosing. This discrepancy has significant implications for patient safety and healthcare costs. Further research is needed to address the issue of dose-selection in drug development.
Zhang has discovered ways to use small catalysts to assemble chiral molecules, accelerating drug discovery and lowering prices. This method is crucial for AIDS drugs, particularly protease inhibitors, which generated $147 billion last year.
A six-week study of 246 black men found that Viagra significantly improved erections and sexual intercourse ability compared to placebo. ED was a common problem among black men, affecting 24% of those aged 40 and above. Treatment with Viagra was well-tolerated, with no serious adverse effects observed.
Researchers isolated bacteria from Mammoth Cave that produce a substance inhibiting angiogenesis, a process crucial for cancer cell growth. The discovery offers new potential tools in the fight against cancer.
The GlaxoSmithKline Drug Discovery and Development Award provides funding for innovative HIV/AIDS research, including therapies aimed at treating infection and preventing transmission. The award is intended to further the development of inventive treatments for HIV/AIDS.
The CF Foundation is leveraging proteomics research to accelerate the discovery of new therapies for cystic fibrosis. By analyzing protein interactions and identifying novel targets, scientists aim to develop effective treatments that can correct faulty cells and prevent disease progression.
New drug targets have been identified by Buck Institute researcher Vivian Hook, Ph.D., that could help treat Alzheimer's Disease. The targets participate in producing the toxic beta-amyloid peptide, which accumulates to form plaques in the brain.
Recent studies suggest that modulating glial inflammation may be an effective approach to delaying onset or slowing progression of neurodegeneration. New compounds described in a study selectively block production of IL-1B, iNOS and NO by activated glia without diminishing the production of other glial proteins.
A team at Cellzome developed a novel approach to systematically use protein interaction maps in drug discovery, enabling researchers to better assess protein roles and predict drug effects. The yeast proteomic map provides a framework for integrating data from literature and experiments.
Dr. Brian L Bray's innovative approach enables mass production of T-20, a 36-amino acid peptide blocking HIV entry. The process opens up new possibilities for peptides as therapeutics and may treat millions of Americans with HIV.
A new bar coding system developed by Purdue University chemists can quickly identify the most biologically active compounds among thousands of candidates. The method uses standard spectrometers and reduces the laborious process to a few hours, cutting down time needed to identify active compounds to zero.
Researchers at Rosetta Inpharmatics used high-quality gene expression data and computational methods to identify novel gene functions. The company's approach enables the deciphering of previously uncharacterized genes, with applications in new drug discovery and development.
Researchers isolated two substances in grapefruit, furanocoumarins, that increase drug absorption by inhibiting an enzyme called CYP3A4. This discovery could lead to improved oral medications and increased reliability of drugs.
Yale University has granted an exclusive license to ArQule Inc. for the development of patent-pending discoveries that could help fight various diseases, including AIDS and emphysema. The Yale chemists' method allows rapid synthesis of alpha-ketoamide-based compounds, which have shown potential in blocking key enzymes called proteases.